Ivantis Raises $25M in Series C

What does Ivantis do?

Ivantis, is the company which developed the novel Hydrus Microstent device for lowering eye pressure for the patients suffering from glaucoma. This company is focused on development of an innovative glaucoma treatment. Their goal is developing a less invasive, more effective option for more than 60 million people globally who are suffering from Primary Open Angle Glaucoma. The company has managed to successfully address their initial goal, now their intention is focusing on innovative treatment development for other conditions in ophthalmology.

How much Ivantis was funded?

The company raised $25M in Series C on January 9, 2017 from Merieux Developpement and RA Capital Management.

Previous funding

$19.12M in undisclosed round on July 28, 2008

$17.26M in Series A on May 31, 2011

$27M in Series B on January 31, 2013 from Delphi Ventures, Ascension Ventures, New Enterprise Associates and MemorialCare Innovation Fund

$5M in Series B on August 20, 2013 from EDB Investments

$14M in Series B on January 13, 2014 from Delphi Ventures, MemorialCare Innovation Fund, New Enterprise Associates, Ascension Ventures, Vertex Ventures, GBS Ventures, EDB Investments and Foresite Capital.

$25M in Series B on September 23, 2014 from Foresite Capital, Delphi Ventures, New Enterprise Associates, Ascension Ventures, GBS Ventures, Vertex Ventures, EDB Investments and MemorialCare Innovation Fund.

What is next for Ivantis?

Ivantis plans on using the latest funding raised for its runway into 2020 and for supporting its commercialization of the Hydrus Microstent in North America. Its approval is anticipated in 2018 by the FDA.

More about Ivantis

Ivantis was founded in 2007. It has its headquarters in Irvine, California. This private company was designed, developed and commercialized new technologies for treating eye disease. The microstent is the size of an eyelash, and is the next gen MIGS device placed through a minimally invasive procedure designed for reducing eye pressure.